Compared side by side
PT-141 vs oxytocin: how they differ
The short answer
Both act in the brain, through different systems: PT-141 is a melanocortin receptor agonist, FDA-approved as Vyleesi for low sexual desire in premenopausal women and taken as needed 1–2 hours before, while oxytocin is the hypothalamic “bonding hormone”, used as a nasal spray. In small studies single oxytocin sprays cut how much people ate at a meal and blunted stress responses, and its only FDA approval is an obstetric injection (Pitocin). Commonly reported: a rise in desire and arousal an hour or so after PT-141, and a subtle calm, warm or more connected feeling after an oxytocin spray.
Side by side
| Compared | PT-141 | Oxytocin |
|---|---|---|
| Category | Sexual health | Metabolic & GLP-1 |
| Also known as | Bremelanotide, PT141, Vyleesi | OT, Love hormone, Oxytocin nasal |
| What it is | An FDA-approved, as-needed treatment for low sexual desire in premenopausal women that acts through brain melanocortin receptors rather than blood flow (flibanserin/Addyi is the other, daily option). | Best known as the "bonding hormone," oxytocin is a hypothalamic neuropeptide with broader effects than most people realize. |
| How it works | Melanocortin receptor agonist (mainly MC4R and MC1R at the approved dose) that acts in the brain to increase sexual desire and arousal; the label says the exact mechanism is unknown. Doesn't work by increasing genital blood flow like PDE5 inhibitors (Viagra etc.), though it can briefly raise blood pressure. FDA-approved as Vyleesi (2019) for acquired, generalized HSDD in premenopausal women. | Hypothalamic neuropeptide with broad effects: single nasal doses cut food intake at a test meal and blunted stress responses in small studies, though an 8-week trial produced no weight loss. It also has anti-inflammatory and metabolic effects (rodent data and small acute human studies). Also supports social bonding. Growing community use for appetite control alongside metabolic peptide protocols. |
| Commonly reported | A noticeable rise in desire and arousal an hour or so after dosing (men often describe firmer or spontaneous erections), nausea that is often worst with the first dose, facial flushing, and headache on dosing days. Frequent use can cause skin darkening. | A subtle calm, warm or more connected feeling shortly after a spray, and for many, little or inconsistent effect from dose to dose. FDA-approved only as an obstetric injection (Pitocin). |
| Studied range | Research range: 0.5–2 mg, starting dose 1.25 mg. Studied in research — not a recommendation. FDA-approved as Vyleesi: 1.75 mg SubQ as needed, at least 45 minutes before sex (at most once a day, 8 times a month), for premenopausal women with acquired, generalized low sexual desire (HSDD). | Research range: 10–40 IU. Studied in research — not a recommendation. |
| How often | As needed, 1–2 hours before | 1–2x daily or as needed |
| Half-life | ~2.7 hours (FDA label; range 1.9–4.0 hours) | ~1–6 min (in blood; nasal doses peak in blood at ~15 min) |
| Route | SubQ injection | Intranasal |
| Typical run | As-needed use. Daily use leads to hyperpigmentation — limit frequency. | As-needed use most common. Animal studies suggest tolerance with frequent daily use, so many users cycle or use it situationally. |
| Evidence | Established: clinical trials or FDA-approved use exists | Moderate: animal studies + some human data |
| Common side effects | Nausea (most common), flushing, blood pressure elevation, spontaneous erections, hyperpigmentation with frequent use | Mild headache, nausea at high doses, possible tolerance with frequent use (seen in animals) |
- Category
- PT-141Sexual health
- OxytocinMetabolic & GLP-1
- Also known as
- PT-141Bremelanotide, PT141, Vyleesi
- OxytocinOT, Love hormone, Oxytocin nasal
- What it is
- PT-141An FDA-approved, as-needed treatment for low sexual desire in premenopausal women that acts through brain melanocortin receptors rather than blood flow (flibanserin/Addyi is the other, daily option).
- OxytocinBest known as the "bonding hormone," oxytocin is a hypothalamic neuropeptide with broader effects than most people realize.
- How it works
- PT-141Melanocortin receptor agonist (mainly MC4R and MC1R at the approved dose) that acts in the brain to increase sexual desire and arousal; the label says the exact mechanism is unknown. Doesn't work by increasing genital blood flow like PDE5 inhibitors (Viagra etc.), though it can briefly raise blood pressure. FDA-approved as Vyleesi (2019) for acquired, generalized HSDD in premenopausal women.
- OxytocinHypothalamic neuropeptide with broad effects: single nasal doses cut food intake at a test meal and blunted stress responses in small studies, though an 8-week trial produced no weight loss. It also has anti-inflammatory and metabolic effects (rodent data and small acute human studies). Also supports social bonding. Growing community use for appetite control alongside metabolic peptide protocols.
- Commonly reported
- PT-141A noticeable rise in desire and arousal an hour or so after dosing (men often describe firmer or spontaneous erections), nausea that is often worst with the first dose, facial flushing, and headache on dosing days. Frequent use can cause skin darkening.
- OxytocinA subtle calm, warm or more connected feeling shortly after a spray, and for many, little or inconsistent effect from dose to dose. FDA-approved only as an obstetric injection (Pitocin).
- Studied range
- PT-141Research range: 0.5–2 mg, starting dose 1.25 mg. Studied in research — not a recommendation. FDA-approved as Vyleesi: 1.75 mg SubQ as needed, at least 45 minutes before sex (at most once a day, 8 times a month), for premenopausal women with acquired, generalized low sexual desire (HSDD).
- OxytocinResearch range: 10–40 IU. Studied in research — not a recommendation.
- How often
- PT-141As needed, 1–2 hours before
- Oxytocin1–2x daily or as needed
- Half-life
- PT-141~2.7 hours (FDA label; range 1.9–4.0 hours)
- Oxytocin~1–6 min (in blood; nasal doses peak in blood at ~15 min)
- Route
- PT-141SubQ injection
- OxytocinIntranasal
- Typical run
- PT-141As-needed use. Daily use leads to hyperpigmentation — limit frequency.
- OxytocinAs-needed use most common. Animal studies suggest tolerance with frequent daily use, so many users cycle or use it situationally.
- Evidence
- PT-141Established: clinical trials or FDA-approved use exists
- OxytocinModerate: animal studies + some human data
- Common side effects
- PT-141Nausea (most common), flushing, blood pressure elevation, spontaneous erections, hyperpigmentation with frequent use
- OxytocinMild headache, nausea at high doses, possible tolerance with frequent use (seen in animals)
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
PT-141
- Day 1–1 First dose — give it 45 minutes
- Day 1–7 Nausea fades with experience
- Day 1–1 Timing and dose are the two dials that matter
Oxytocin
- Day 1–7 Use it when you need it
- Day 7–28 Watch for tolerance creep
- Day 28–90 Consolidated situational use
Together or one or the other
PT-141 and oxytocin are a common stack: each lists the other among its common stacks.
Community · Oxytocin
Connection + desire
Oxytocin + PT-141 is a common situational stack for intimacy. PT-141 drives the desire side (melanocortin receptors) and oxytocin adds the connection/bonding side. Users keep it intermittent, not a routine.
Questions people ask
How long do PT-141 and oxytocin last?
The half-life of PT-141 is ~2.7 hours (FDA label; range 1.9–4.0 hours). The half-life of oxytocin is ~1–6 min (in blood; nasal doses peak in blood at ~15 min).
How often are PT-141 and oxytocin taken?
PT-141: as needed, 1–2 hours before. Route: SubQ injection. Oxytocin: 1–2x daily or as needed. Route: Intranasal.
How are PT-141 and oxytocin dosed in research?
The research range for PT-141 is 0.5–2 mg, with a 1.25 mg starting dose. Studied in research — not a recommendation. FDA-approved as Vyleesi: 1.75 mg SubQ as needed, at least 45 minutes before sex (at most once a day, 8 times a month), for premenopausal women with acquired, generalized low sexual desire (HSDD). The research range for oxytocin is 10–40 IU. Studied in research — not a recommendation.
What are the common side effects of PT-141 and oxytocin?
For PT-141, the library lists: nausea (most common), flushing, blood pressure elevation, spontaneous erections, hyperpigmentation with frequent use. For oxytocin: mild headache, nausea at high doses, possible tolerance with frequent use (seen in animals).
Are PT-141 and oxytocin taken together?
PT-141 and oxytocin are a common stack: each lists the other among its common stacks. Oxytocin + PT-141 is a common situational stack for intimacy. PT-141 drives the desire side (melanocortin receptors) and oxytocin adds the connection/bonding side. Users keep it intermittent, not a routine.